United Kingdom-based AstraZeneca has achieved its primary endpoint in the phase III Tulip two trial of new medicine anifrolumab for systemic lupus erythematosus, it is reported today.
The company says that the product has showcased a statistically-significant and clinically-meaningful decrease in disease activity compared to placebo in the trial. Both arms received standard of care in the study.
The product is a fully human monoclonal antibody, which binds to subunit one of the type one interferon receptor, enabling the blocking of the activity of all type I interferons including IFN-alpha, IFN-beta and IFN-omega. Type I interferons are cytokines chosen in the inflammatory pathways. British Isles Lupus Assessment Group based Composite Lupus Assessment (BICLA) has been utilised for the measurement of reduction at week 52. Tulip 2 was the second phase III trial designed to assess the safety and efficacy of anifrolumab as a treatment for adults with moderate-to-severe systemic lupus erythematosus.
BenevolentAI reports positive Phase Ia safety and pharmacokinetic data for BEN-8744
Thermo Fisher Scientific unveils CorEvitas registry for generalized pustular psoriasis
Nektar Therapeutics commences Phase 2b rezpegaldesleukin clinical trial for alopecia areata
Innovent Biologics doses first participant in first-in-human phase one clinical trial of IBI3002
Ananda Developments secures CBD Drug Supply Agreement for endometriosis clinical trial
Trellus Health secures agreement with major US health plan for IBD management
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP